Abstract
Primary and secondary prevention strategies for Alzheimers disease (AD) are urgently needed. We have initiated a five-year prospective prevention study involving patients spontaneously reporting memory complaints. The primary objective is to determine the effect of treatment with EGb 761® on the rate of conversion from memory complaints to AD using survival analysis. Ambulatory patients aged at least 70 years who spontaneously reported a memory complaint during a GP or memory centre consultation were eligible for inclusion. Patients with major objective memory impairment or clinically relevant symptoms of anxiety and depression were excluded. Subjects were randomised to receive either EGb 761 120mg bid or matching placebo. Participants undergo an annual visit at a memory centre, where a series of neuropsychological tests are administered to assess cognitive function (Grober and Buschke, Trail-Making and controlled oral word association tests) and cognitive status (MMS and CDR). Functional status is evaluated with the Instrumental Activities of Daily Living questionnaire. The primary outcome is the transition to a diagnosis of AD (DSM-IV and NINCDSADRDA criteria), determined at the annual memory centre visit. A total of 4066 patients were screened for participation, of whom 2854 fulfilled the eligibility criteria and were entered into the study. Their mean age was 76.8±4.4 years and 66.7% were female. The mean MMSE score was 27.8±1.7 and 55.5% presented a CDR score of 0.5. This study will enable us to evaluate the efficacy of EGb761 in the prevention of AD, and to assess the usefulness of various baseline characteristics as predictors of conversion to AD in this population.
Keywords: Memory complaints, Alzheimer's disease, clinical trial, secondary prevention, EGb 761
Current Alzheimer Research
Title: GuidAge Study: A 5-Year Double Blind, Randomised Trial of EGb 761 for the Prevention of Alzheimers Disease in Elderly Subjects with Memory Complaints. I. Rationale, Design and Baseline Data
Volume: 5 Issue: 4
Author(s): Sandrine Andrieu, Pierre-Jean Ousset, Nicola Coley, Mehemed Ouzid, Helene Mathiex-Fortunet and Bruno Vellas
Affiliation:
Keywords: Memory complaints, Alzheimer's disease, clinical trial, secondary prevention, EGb 761
Abstract: Primary and secondary prevention strategies for Alzheimers disease (AD) are urgently needed. We have initiated a five-year prospective prevention study involving patients spontaneously reporting memory complaints. The primary objective is to determine the effect of treatment with EGb 761® on the rate of conversion from memory complaints to AD using survival analysis. Ambulatory patients aged at least 70 years who spontaneously reported a memory complaint during a GP or memory centre consultation were eligible for inclusion. Patients with major objective memory impairment or clinically relevant symptoms of anxiety and depression were excluded. Subjects were randomised to receive either EGb 761 120mg bid or matching placebo. Participants undergo an annual visit at a memory centre, where a series of neuropsychological tests are administered to assess cognitive function (Grober and Buschke, Trail-Making and controlled oral word association tests) and cognitive status (MMS and CDR). Functional status is evaluated with the Instrumental Activities of Daily Living questionnaire. The primary outcome is the transition to a diagnosis of AD (DSM-IV and NINCDSADRDA criteria), determined at the annual memory centre visit. A total of 4066 patients were screened for participation, of whom 2854 fulfilled the eligibility criteria and were entered into the study. Their mean age was 76.8±4.4 years and 66.7% were female. The mean MMSE score was 27.8±1.7 and 55.5% presented a CDR score of 0.5. This study will enable us to evaluate the efficacy of EGb761 in the prevention of AD, and to assess the usefulness of various baseline characteristics as predictors of conversion to AD in this population.
Export Options
About this article
Cite this article as:
Andrieu Sandrine, Ousset Pierre-Jean, Coley Nicola, Ouzid Mehemed, Mathiex-Fortunet Helene and Vellas Bruno, GuidAge Study: A 5-Year Double Blind, Randomised Trial of EGb 761 for the Prevention of Alzheimers Disease in Elderly Subjects with Memory Complaints. I. Rationale, Design and Baseline Data, Current Alzheimer Research 2008; 5 (4) . https://dx.doi.org/10.2174/156720508785132271
DOI https://dx.doi.org/10.2174/156720508785132271 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Everyday Cognition Scale Items that Best Discriminate Between and Predict Progression From Clinically Normal to Mild Cognitive Impairment
Current Alzheimer Research Glycogen Synthase Kinase-3 in Neurodegeneration and Neuroprotection:Lessons from Lithium
Current Alzheimer Research Histamine H3 Antagonists as Wake-Promoting and Pro-Cognitive Agents
Current Topics in Medicinal Chemistry Molecular Insight into the Crosstalk of UPS Components and Alzheimer’s Disease
Current Protein & Peptide Science Pharmacokinetic and Pharmacodynamic Properties of Anti-VEGF Drugs After Intravitreal Injection
Current Drug Metabolism Classic β-Amyloid Deposits Cluster Around Large Diameter Blood Vessels Rather than Capillaries in Sporadic Alzheimers Disease
Current Neurovascular Research Adolescent HIV-1 Transgenic Rats: Evidence for Dopaminergic Alterations in Behavior and Neurochemistry Revealed by Methamphetamine Challenge
Current HIV Research Semantic Memory Disorders in Alzheimers Disease: Clues from Semantic Priming Effects
Current Alzheimer Research Chemical and Molecular Aspects on Interactions of Galanthamine and Its Derivatives with Cholinesterases
Current Pharmaceutical Biotechnology Mobilization and Redistribution of Default Mode Network from Resting State to Task State in Amnestic Mild Cognitive Impairment
Current Alzheimer Research Comparative Study of Non-High Density Lipoproteins Cholesterol Level and Lipid Profile in Pre-Diabetic and Diabetic Patients
CNS & Neurological Disorders - Drug Targets Vascular Effects of Estrogenic Menopausal Hormone Therapy
Reviews on Recent Clinical Trials Role of Prolyl Endopeptidase in Intracellular Transport and Protein Secretion
CNS & Neurological Disorders - Drug Targets The Epidemiology and Health Effects of Tobacco Use
Current Pediatric Reviews The Relationship Between Plasma Aβ Levels, Cognitive Function and Brain Volumetrics: Sydney Memory and Ageing Study
Current Alzheimer Research Metformin Eased Cognitive Impairment Induced by Chronic L-methionine Administration: Potential Role of Oxidative Stress
Current Neuropharmacology Effectiveness of a Standardized and Specific Follow-Up in Memory Centers in Patients with Alzheimer’s Disease
Current Alzheimer Research Editorial: “Phytochemicals for Human Diseases: An Update”
Current Drug Targets Editorial (Thematic Issue: Phytochemicals for Human Diseases: An Update)
Current Pharmaceutical Biotechnology Central Selective Acetylcholinesterase Inhibitor with Neurotrophic Activity Structure-Activity Relationships of TAK-147 and Related Compounds
Current Medicinal Chemistry